The U.S. Food and Drug Administration has approved top-selling Abilify as a treatment for autism-related irritability in children from the ages of 6 to 17, drug maker Bristol-Myers Squibb Co. said Friday.

They call it the "Botax." The White House and Senate Democrats have turned to a proposal to tax breast implants, tummy tucks, wrinkle-smoothing injections and other procedures as they search for ways to pay for costly health care overhaul plans.

Moody's Investors Service issued a negative opinion on the pharmaceutical industry Thursday, saying drugmaker credit ratings will be under pressure until early 2012 because they won't be able to fully replace revenue from best-sellers that go off-patent.

Democrats in the U.S. Senate cleared the first procedural hurdle for sweeping healthcare reform on Saturday by voting to open debate on the historic legislation.

A UBS analyst said Wednesday that medical technology stocks are trading at attractive prices, and raised his ratings or price targets on nine of them.

Congressional Democrats are seeking government investigations into recent price increases of brand-name prescription drugs, as Congress finalizes an overhaul of the healthcare system.

Par Pharmaceutical Co. said Monday it received marketing approval for a generic version of Johnson & Johnson's extended-release chronic pain drug Ultram ER, and has started shipping the drug.

Even as the US market continues to rally, many institutional investors are trimming their US holdings and putting more money in foreign stocks—especially those in emerging markets.

News Web sites are starting to look a lot less like newspapers and a lot more like television, says the New York Times.

Cancer patients who took drugs to cut the risk of anemia were twice as likely to develop blood clots in the lungs or legs as other patients, a decade-long study of more than 55,000 cancer patients has found.

The number of newly laid-off workers filing claims for unemployment benefits falls to the lowest level in 10 months, evidence that job cuts are easing as the economy slowly heals.

As more nervousness creeps into the US stock market, investors are sharpening their look at overseas opportunities where growth is outpacing the US recovery.

As CEO and primary shareholder of Berkshire Hathaway (BRK), Warren Buffett, the world's most famous investor, has developed a well-known reputation of buying big stakes in companies he believes in. When Buffett buys shares of a company for BRK, the markets translate his moves as a vote of confidence for a firm's continued success. Although Berkshire Hathaway's holdings change, the company's most recent SEC filings* reveal where the Oracle of Omaha is most heavily invested. Here are the 15 publicly traded stocks, by value, that are the biggest holdings of Berkshire Hathaway.

Johnson & Johnson said Tuesday it will cut up to about 8,000 jobs and streamline its operations in an effort to cut costs as it braces for changes in the health care industry.

Johnson & Johnson will eliminate about 6 percent to 7 percent of its global workforce, or some 7,000 to 8,000 positions, as the diversified healthcare company restructures and seeks cost savings, the company said Tuesday.